Rapid-acting insulin analogues: When randomized clinical trial results do not help

Diabetic Medicine

Volumn 17, Issue SUPPL. 2, 2000, Pages 6-8

  Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; BLOOD GLUCOSE MONITORING; CASE REPORT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; SHORT SURVEY;

ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; EVIDENCE-BASED MEDICINE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0033766384     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00361-4.x     Document Type: Short Survey

References (12)

1. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment
2. Improved mealtime treatment of diabetes mellitus using an insulin analogue
3. Use of insulin aspart, a fast-acting insulin analog, as meal-time insulin in the management of patients with Type 1 diabetes
4. Insulin aspart versus human insulin in the management of long-term blood glucose control in Type 1 diabetes: A randomized controlled trial
5. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients
6. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients
7. [Lys (B28),Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin
8. Time-action profile of the insulin analogue B28Asp
9. Optimization of evening insulin dose in patients using the short-acting insulin analogue lispro
10. Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal
11. Opimal provision of daytime NPH insulin in patients using the insulin analog lispro